Benefits And Risks of Vildagliptin/Metformin Versus Sulphonylureas/Metformin Combination Therapy In Type 2 Diabetes Mellitus (T2dm) From Patient’s Perspective: Real-World Data

Abstract

A615Objectives: The approach of the diabetes register named DIAREG is to display the health care reality of patients with type 2 diabetes (T2D) in Germany. In comparison to other existing diabetes registries, DIAREG analyses patient-reported outcomes (PRO) in order to illustrate patient reported quality of life (QoL). MethOds: In July 2013 DIAREG was started including retrospective as well as prospective data from over 100 office based physicians (general practitioner and diabetologists). DIAREG analysis is based on 6 different PRO: generic quality of life questionnaire (SF-36); audit of diabetes-dependent quality of life (ADDQoL); diabetes treatment satisfaction questionnaire (DTSQ); impact of weight quality of life (IWQoL-Lite); Center of Epidemiological Studies Depression Scale (CES-D) and WHO five well being index (WHO-5). Results: By June 2015 more than 2,000 T2D patients were included in the register, involving an observation period of 22 months. Within this time frame PRO of more than 300 patients were completed. The mean age of T2D patients was 68.5 years, whereas 48% of the patient population was older than 70 years. According to a subgroup analysis of 1,646 patients, 16% of the patients were recruited by officebased diabetologists and the majority of 84% by primary care physicians. About 20% of these patients had their therapy changed within the last year due to inadequate HbA1C control. An adjustment of the current therapy was conducted at 81%, a change of the therapy at 46%. Main focus of the physicians for changing the therapy pattern was the decrease of the HbA1C. Based on this platform, further evaluation on QoL will be started. cOnclusiOns: In conclusion, DIAREG shows the treatment reality from the patient and physician perspective and will therefore describe the health care situation and QoL of diabetes patients in Germany.

Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study

“…The higher SU-associated T2DM hospitalization risk may underpin the disadvantage of higher rates of hypoglycaemia associated with SU therapy [ 20 ], something which has also been confirmed by earlier studies and reported in a recently published review [ 21 – 23 ]. In addition, another systematic review and meta-analysis as well as another study found that patients receiving SU treatment had an increased all-cause mortality risk [ 16 , 24 ]; this, however, could not be confirmed in every study [ 25 ].…”